Jehonathan H. Pinthus, MD, PhD, FRCSC

Jehonathan H. Pinthus, MD, PhD, FRCSC

McMaster University

Hamilton, ON, Canada

Dr. Pinthus is an Associate Professor in the Department of Surgery’s Division of Urology at McMaster University in Hamilton, Ontario. He is a surgical oncologist-urologist who completed his MD at the Hebrew University in Jerusalem, Israel, and his urology training at the Sheba Medical Centre at Tel Aviv University in Israel. He then completed 2.5 years of an SUO-accredited Fellowship in Uro-Oncology at the University of Toronto. Dr. Pinthus earned his PhD at the Weizmann Institute of Science in Rehovot, Israel, working on gene immunotherapy of prostate cancer. He is heading a basic and translational research laboratory at McMaster University and his research interests relate to how patients’ individual host factors and metabolism affect prostate cancer growth and response to therapy. Dr. Pinthus has published more than 80 peer-reviewed papers and several book chapters. He is a member of the editorial board of European Urology, Prostate Cancer, and Prostatic Disease. Dr. Pinthus is the principal investigator on many distinguished research grants, including a $3.5 million Movember-Prostate Cancer Canada grant titled “Role of androgen deprivation therapy in cardiovascular disease - a longitudinal prostate cancer study (RADICAL PC).” This study is intended to prospectively address the potential link between prostate cancer in general and androgen deprivation therapy (ADT) in particular and an increased risk of cardiovascular disease.

Disclosures:

Articles by Jehonathan H. Pinthus, MD, PhD, FRCSC

Thromboembolic Complications in Bladder Cancer

Jehonathan H. Pinthus, MD, PhD, FRCSC, explains factors that influence a bladder cancer patient’s risk of thromboembolic complications and prevention methods. His discussion includes the optimal timing of venous thromboembolism (VTE) prophylaxis after radical cystectomy, how cisplatin-based neoadjuvant chemotherapy effects thromboembolic events, and his opinion on current guidelines.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -